Veröffentlichungen

Highlights vom Kongress ASCO 2022 zur Therapie mit CDK4/6-Inhibitoren

Statement Dr. med. Thomas Göhler zur PALOMA-2-Studie: Postmenopausale Frauen mit HR+ / HER2- metastaiertem Brustkrebs ohne Vorbehandlung

  • Trastuzumab treatment of early breast cancer: long-term results from a prospective observation study, including a large cohort of elderly patients

    • Autoren: Dall P. 1, Lenzen G. 2, Göhler T. 3, Lerchenmüller C. 4, Feisel-Schwickeradi G. 5, Koch T. 6, Eggert J. 7, Hellmann V. 8, Schindler C. 9, Wilke J. 10, Tesch H. 11, Selbach J. 12, Hinke A. 13
    • Institutionen: 1 Städtisches Klinikum, Frauenklinik, Lüneburg, 2 Praxis, Osnabrück, 3 Praxis Dresden, 4 Praxis Münster, 5 Klinikum Kassel, 6 Klinikum Nürnberg Nord, 7 Praxis Moers, 8 Praxis Günzburg, 9 Praxis Leipzig, 10 Praxis Fürth, 11 Onkologie Bethanien, Frankfurt, 12 Praxis Duisburg, 13 WISP, Langenfeld
    • San Antonio 2013 und Deutscher Krebskongreß 2014

  • Intravenous and oral treosulfan in the routine treatment of ovarian cancer: first results of a German non-interventional study (NIS)

    • Autoren: Radoslav Chekerov Charité Berlin, Hans-Ulrich Ulmer St. Klinikum Karlsruhe, Dietmar Reichert Onkolog. Gemeinschaftspraxis Westerstede, Thomas Göhler Onkozentrum Dresden, Peter Klare Praxisklinik Berlin, Uwe Sauer Gemeinschaftspraxis Nordhorn, Arthur Wischnik Klinikum Augsburg, Ursula Vehling-Kaiser H.O.T. Landshut, Martin Becker Onkologische Praxis Minden, Ulrich Hutzschnreuther Gemeinschaftspraxis Nordhorn, Andreas Ammon Onkologische Praxis Göttingen, Elke Heidrich-Lorsbach Alcedis GmbH, Jalid Sehouli Charité Berlin
    • ESGO 2013

  • Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2)

    • Autoren: Volker Moebus, Helmut Forstbauer, Grischa Wachsmann, Andreas Schneeweiss, Angelika Ober, Ekkehard von Abel, Petra Krabisch, Heinz-Gert Hoeffkes, Karin Kast, Bernd Christensen, Michael Niedermeier, Mustafa Deryal, Christoph Uleer, Yvonne Fauster, Thomas Goehler, Sibylle Loibl, Valentina Nekljudova, Gunter Von Minckwitz
    • ASCO 2013

  • Overall survival of specific HCC patient subgroups in prospective, non-interventional INSIGHT study treated with sorafenib

    • Autoren: Koschny R., Schott E., Galle P.R., Göhler T., Malfertheiner P., Stauber R., Buder R., Bernard I., Gerken G.
    • ESMO 2013

  • Secondary resection in a general mCRC population with cetuximab-based first-line treatment: Interim analysis of the german noninterventional study ERBITAG

    • Autoren: Ulf P Neumann, Thomas Goehler, Gernot Reich, Michael Schwerdtfeger, Patrick Stuebs, Karsten G Stenzel, Friedrich Overkamp
    • ASCO 2013

  • Febrile neutropenia (FN) risk assessment and granulocyte colony-stimulating factor (G-CSF) guideline adherence in patients with breast cancer – results from a German prospective multicentre observational study (PROTECT)

    • Autoren: C. Kurbacher, H. Eschenburg, C.-C. Steffens, M. Schmidt, B. Otremba, K. Hübel, H. Eustermann
    • SABSC 2012

  • Topotecan-Carboplatin versus Standard Platinum Combinations in Patients with Platinum-sensitive recurrent Ovarian Cancer0 – the GCIG Intergroup „HECTOR“-Phase Trial

    • Autoren: S. Mahner, R. Chekerov, A. Zeimet, E. Garcia-Martinez, L. Hanker, P. Klare, U. Denison, A. Burges, S. Dörfel, A. Hasenburg, R. Richter, H.-G. Strauss, G. Emons, W. Schröder, W. Meier, J. Sehouli
    • NOGGO, AGO-Germany, AGO-Austria, GEICO, GCIG
    • 14th Biennial Meeting IGCS, October 2012

  • Interimsanalyse zum Gesamtüberleben in verschiedenen Subpopulationen der prospektiven, nicht-interventionellen INSIGHT-Studie mit Sorafenib bei Patienten mit hepatozellulärem Karzinom

    • Autoren: P. Malfertheiner, T.M. Ganten, E.Schott, P.R. Galle, T.Göhler et al.
    • DGHO 2012

  • Febrile neutropenia (FN) risk assessment and granulocyte colony-stimulating factor (G-CSF) guideline adherence in patients with solid tumours or lymphoma – results from a German prospective multicentre observational study (PROTECT)

    • Autoren: C. Kurbacher, H. Eschenburg, C.-C. Steffens, M. Schmidt, B. Otremba, K. Hübel, H. Eustermann, A. Friebel, T. Goehler
    • DGHO 2012

  • Interimanalysis of Overall Survival per subgroups in the prospective, non-interventional INSIGHT Study in patients with hepatocellular carcinoma treated with Sorafenib

    • Autoren: Ganten T.M., Schott E., Galle P.R., Göhler T., Malfertheiner P., Stauber R., Buder R., Achilles K., Gerken G.
    • ESMO 2012

  • Reduced HFSR incidence observed in a randomized phase II study in advanced breast cancer patients treated with Sorafenib and Paclitaxel by initial ramp-up dose escalation (PASO)

    • Autoren: Overkamp, Steffens, Abenhardt, Lerchenmüller, Nusch, Göhler, Groschek, Hegewisch-Becker,Marschner, Rösel, Salat and Decker
    • DKK 2012

  • Trastuzumab treatment in patients with advanced breast cancer (ABC) confined to locoregional and skeletal sites – Results from a large non-interventional study

    • Autoren: Christian Jackisch, Winfried Schoenegg, Johannes Selbach, Manfred Welslau, Hanns-Detlev Harich, Jan Schroeder, Marcus Schmidt, Thomas Goehler, Axel Hinke, Heidi Eustermann, Ralf Ringel
    • ASCO 2012

Weiterlesen